J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
John M. A. Northover,Rob Glynne-Jones,David Sebag-Montefiore,Roger D James,Helen Meadows,S Wan,Mark Jitlal,Jonathan A. Ledermann +7 more
TL;DR: The clear benefit of chemoradiation outweighs an early excess risk of non-anal cancer deaths, and can still be seen 12 years after treatment, and only 11 patients suffered a locoregional relapse as a first event after 5 years, which may influence the choice of end points in future studies.
Journal ArticleDOI
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
T. Ruers,Cornelis J. A. Punt,F. van Coevorden,Jean-Pierre E. N. Pierie,I. Borel-Rinkes,Jonathan A. Ledermann,G. Poston,Wolf O. Bechstein,M.A. Lentz,Murielle Mauer,E. Van Cutsem,Manfred P. Lutz,Bernard Nordlinger +12 more
TL;DR: The study met the primary end point on 30-month OS; however, the results in the control arm were in the same range; at present, the ultimate effect of RFA on OS remains uncertain.
Journal ArticleDOI
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
TL;DR: Accumulating evidence suggests that PARPi may have a wider application in the treatment of sporadic high-grade serous ovarian cancer, and cancers defective in DNA repair pathways, such as prostate, endometrial, and pancreatic cancers.
Journal ArticleDOI
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan A. Ledermann,Philipp Harter,Charlie Gourley,Michael Friedlander,Ignace Vergote,Gordon J. S. Rustin,Clare L. Scott,Werner Meier,Ronnie Shapira-Frommer,Tamar Safra,Daniela Matei,Anitra Fielding,Stuart Spencer,Brian Dougherty,Maria Orr,Darren Hodgson,J. Carl Barrett,Ursula A. Matulonis +17 more
TL;DR: Poly(ADp-ribose) polymerase inhibitors have been investigated as treatment for a number of tumors, including those due to BRCA mutations, and one potent oral poly(ADP-riboses) is found to be effective.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Romerai D'Amico,Anthony Fyles,Marie-Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Sergio Gribaudo,Diane Provencher,Chantal Hanzen,Roy F.P.M. Kruitwagen,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Andrea Lissoni,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,M McCormack,K Whitmarsh,R Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,M Adusumalli,Anjana Anand,R Wade,Alexandra J. Stewart,W Taylor,L.C.H.W. Lutgens,Harmen Hollema,Elisabeth Pras,An Snyers,GH Westerveld,J.J. Jobsen,Annerie Slot,J.W.M. Mens,Tanja C. Stam,B. van Triest,E. Van der Steen-Banasik,Kaj De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Colin D. Johnson,Anne Capp,Roldano Fossati,Alessandro Colombo,Silvestro Carinelli,Annamaria Ferrero,G Artioli,C Davidson,C M McLachlin,Prafull Ghatage,Pvc Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer and did a post-hoc survival analysis to investigate patterns of recurrence.